Clinical guideline · 2025
European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie's Disease
Salonia A, Capogrosso P, Boeri L, Cocci A, Corona G, Dinkelman-Smit M, Falcone M, Jensen CF, Gül M, Kalkanli A, Kadioğlu A, Martinez-Salamanca JI, Afonso Morgado L, Russo GI, Serefoğlu EC, Verze P, Minhas S (2025). European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie's Disease. European Urology. doi:10.1016/j.eururo.2025.04.010
The 2025 EAU guideline adopts the ISSM definition of PE; after the subtype is identified and expectations are discussed, it considers medication first-line for lifelong PE, while treating the underlying cause comes first in acquired PE.
Summary
This article summarises the 2025 update of the European Association of Urology (EAU) guidelines on sexual and reproductive health, covering hypogonadism, erectile dysfunction, premature ejaculation (PE) and Peyronie's disease. The panel updated its systematic review with research published in 2021–2024 from Medline, EMBASE and the Cochrane Libraries, and graded each recommendation on the balance of benefits and harms, the quality of the evidence and patient preferences.
For PE, the EAU adopts the International Society for Sexual Medicine definition. Once the subtype has been established, the patient's expectations should be discussed thoroughly. The guideline states that pharmacotherapy must be considered first-line treatment for lifelong PE, whereas for acquired PE the initial goal is to treat the underlying cause (for example erectile dysfunction).
The full online chapter (Disorders of ejaculation, checked 8 October 2026) adds detail on drug treatment. Its recommendations (section 6.2.7) are, each with a strong rating: treat erectile dysfunction (ED), other sexual dysfunction or genitourinary infection first; use dapoxetine or a lidocaine/prilocaine spray as first-line treatment for lifelong PE; use off-label daily SSRIs (selective serotonin reuptake inhibitors) or daily or on-demand clomipramine as second-line alternatives; use off-label tramadol with caution as a third-line, on-demand alternative; and use phosphodiesterase type 5 inhibitors (PDE5 inhibitors, the erection medicines) alone or combined with other therapies in men with PE without ED.
On daily SSRIs (section 6.2.6.b.2), the chapter states that trials used paroxetine 20–40 mg, sertraline 25–200 mg, fluoxetine 10–60 mg and clomipramine 25–50 mg; that several meta-analyses suggest SSRIs may increase the geometric mean latency 2.6- to 13.2-fold; that the delay may start a few days after starting but is more evident after one to two weeks; and that tachyphylaxis (a fading response) may occur after 6 to 12 months. Common side effects listed are fatigue, drowsiness, yawning, nausea, vomiting, dry mouth, diarrhoea and sweating, usually mild and improving after two to three weeks; decreased libido, anorgasmia, anejaculation and ED have also been reported. The chapter advises caution in prescribing SSRIs to adolescents aged 18 or under and to men with comorbid depression, particularly with suicidal ideation; advises men trying to conceive to avoid them because of detrimental effects on sperm; and advises against sudden cessation or rapid dose reduction because of SSRI withdrawal syndrome.
On PDE5 inhibitors (sections 6.2.6.b.1 and 6.2.6.b.5), it reports that in the studies it cites, sildenafil did not significantly improve latency but increased confidence, perceived ejaculatory control and overall sexual satisfaction, and reduced anxiety and the refractory time to a second erection after ejaculation; that several open-label studies and a network meta-analysis found a PDE5 inhibitor plus an SSRI superior to an SSRI alone; and that a randomised trial found dapoxetine plus sildenafil improved latency and patient-reported outcomes compared with either drug alone.
Limitations
The journal article is a summary; the detail above comes from the full online chapter, which the EAU revises each year, so wording and section numbers can change. Guideline wording reflects European regulatory approvals, which differ from other regions.
What it means for you
The leading European urology guideline treats lifelong and acquired PE differently. If PE started later in life, a doctor will first look for a cause such as erection difficulties, anxiety or a relationship change. If it has been there from the start, European guidance puts medication first, which is a reasonable option to discuss with a doctor alongside non-drug approaches.